Save the date for our Xtalks Webinar on Thursday, January 25, 2024, from 11 a.m. – 12 p.m. ET:

“A Promising Biomarker for Tumor Immunogenicity: Unveiling the Potential of Immunoscore IC® (CD8/PDL1) in Drug Development.”

Discover the potential of Immunoscore IC® (CD8/PDL1), a promising biomarker for tumor immunogenicity in drug development with our speakers, Jérôme Galon, Ph.D., SVP and Scientific Executive Director at Veracyte, and Jacques Fieschi, Ph.D., VP Research & Development at Veracyte.

Our experts will provide an in-depth review of the analytical performance, clinical relevance, and efficacy of Veracyte’s Immunoscore IC® (CD8/PDL1), with a focus on metastatic colorectal cancer (mCRC) and non-small cell lung cancer (NSCLC).

If you are unable to attend the live session, you can still register to access the webinar recording.